Hypertension Center

AMA Panel Creates Category I CPT Codes for Renal Denervation

October 1, 2026—The American Medical Association (AMA) Current Procedural Terminology (CPT) Editorial Panel has created two category I CPT codes describing renal denervation (RDN).

Pulnovo’s PADN-HF-PH Trial Results Presented and Published

September 18, 2026—Pulnovo Medical, a China-based developer of medical devices for pulmonary hypertension (PH) and heart failure (HF), announced that results from the PADN-HF-PH trial were presented at the European Society of Cardiology’s ESC Congress 2026 and simultaneously published by Hang Zhang, MD, et al in The New England Journal of Medicine.

Medtronic’s Symplicity Spyral RDN Treatment Evaluated for Reducing Albuminuria in Renal Disease

June 8, 2026—Medtronic announced that new results from the Global SYMPLICITY Registry DEFINE (GSR DEFINE) demonstrated significant reductions in albuminuria in patients with hypertensive renal disease after treatment with radiofrequency renal denervation (RDN).

EMBRACE to Study Medtronic’s Symplicity Spyral RDN System With Staged PCI

March 31, 2026—Medtronic announced it is supporting the investigator-initiated EMBRACE trial of the company’s Symplicity Spyral renal denervation (RDN).

Verve’s United States Pilot Trial of Renal Pelvic Denervation Therapy Enrolls First Patient

March 11, 2026—Verve Medical, a developer of noninvasive renal pelvic denervation (RPD) technology, announced the treatment of the first patient in its randomized, double-blinded United States pilot clinical trial for the treatment of uncontrolled hypertension.

Symplicity Spyral RDN Studied in Pooled Analyses From SPYRAL HTN Program

March 11, 2026—New analyses from the SPYRAL HTN clinical study program presented at CRT 2026 reported long-term outcomes with the Symplicity Spyral radiofrequency (RF) renal denervation (RDN) system (Medtronic), including a pooled 3-year efficacy analysis, a study of hypertensive urgencies, and the design of the SPYRAL CARE real-world study.

Otsuka’s Paradise uRDN System Launched in Japan With National Health Insurance Coverage


March 2, 2026—Otsuka Medical Devices Co., Ltd. and Otsuka Pharmaceutical Co., Ltd., announced the commercial launch of the Paradise ultrasound renal denervation (uRDN) system.

Medtronic Secures Japan Reimbursement for Spyral RDN

February 19, 2026—Medtronic plc announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted reimbursement approval for the Symplicity Spyral renal denervation (RDN) system (Medtronic) for the treatment of resistant hypertension.

Neurotronic’s Neuviant Multiorgan Denervation Studied to Treat Type 2 Diabetes and Hypertension 

November 17, 2025—Neurotronic, Inc. announced the first clinical outcomes of the NECTAR III and NECTAR IV trials evaluating the company’s Neuviant multiorgan denervation (MDN) system in patients with both type 2 diabetes mellitus (T2DM) and hypertension (HTN).

Long-Term SPYRAL HTN-ON MED Data Presented for Medtronic’s Symplicity Spyral RDN System

October 26, 2025—Medtronic announced that long-term results from its final report of the SPYRAL HTN-ON MED trial showed that patients treated with the company’s radiofrequency-based Symplicity Spyral renal denervation (RDN) procedure experienced significantly greater reductions in blood pressure compared to sham patients through 3 years.

Medtronic’s Symplicity Spyral Renal Denervation System Approved in Japan

September 2, 2025—Medtronic announced that its Symplicity Spyral renal denervation (RDN) system has been approved by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for the treatment of resistant hypertension.